Xlife Sciences invests in 4D LifetecOctober 19, 2023
Xlife Sciences AG has invested CHF 23.3 million in 4D Lifetec AG , acquiring a 20% stake in the company.
With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest™ in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.
4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker that has proven its high sensitivity already in cancer stages I and II in numerous clinical studies. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.
Comments on the deal
Dr. Arne-Christian Faisst, Co-founder and Chairman of 4D Lifetec said: “Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists. This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.”
Dr. Giancarlo Rizzoli, CEO of 4D Lifetec, said: “The combined forces of 4D Lifetec and Xlife Sciences are a game changer, paving the way to new horizons in digital health. We look forward to our continued collaboration.”
Oliver R. Baumann, from Xlife Sciences, said: “We are excited to embark on this journey with 4D Lifetec. Together, we will lead the way in leveraging cutting-edge AI technologies to enhance healthcare solutions and redefine diagnostics.”